A Study of MORAb-009 in Patients With Solid Tumor

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT01018784

First Posted: November 25, 2009

Last Update Posted: January 21, 2016

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Eisai Inc. ( Eisai Co., Ltd. )

Purpose

MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.

Condition	Intervention	Phase
Cancer Mesothelin-positive	Drug: MORAb-009	Phase 1


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	A Phase 1 Study of MORAb-009 in Patients With Solid Tumor

Further study details as provided by Eisai Inc. ( Eisai Co., Ltd. ):

Primary Outcome Measures:

To investigate dose-limiting toxicity and estimate maximum tolerated dose. [ Time Frame: 4 Weeks ]

Secondary Outcome Measures:

The best overall response rate in the RECIST evaluation and the preliminary evaluation calculating the frequency of Completed response and Partial Response. [ Time Frame: During Study ]


Enrollment:	17
Study Start Date:	November 2009
Study Completion Date:	February 2013
Primary Completion Date:	May 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: MORAb-009	Drug: MORAb-009 MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	20 Years to 79 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria;

Japanese male and female patients aged from 20 to less than 80 years at obtaining informed consent
Patient with histologically or cytologically diagnosed solid tumor
Patient who is mesothelin-positive confirmed by immunohistochemistry (IHC) (except for pancreatic cancer and mesothelioma that mesothelin-positive is frequently reported)
Patient with solid tumor who is non responder to or resistant to standard therapy and has no other appropriate treatment
Performance Status (PS) is 0 to 1 by Eastern Cooperative Oncology Group ECOG criteria

Exclusion criteria

Brain metastasis presenting clinical symptoms or requiring medical treatment
Serious and systemic infection requiring medical treatment
History of hypersensitivity to protein formulations including monoclonal antibody
With active multiple carcinoma (except for carcinoma in situ and intramucosal carcinoma)
With celomic fluid (pleural effusion or ascites) uncontrolled by drainage, or with a large volume of celomic fluid

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01018784

Locations


Japan

Sayama-shi, Osaka, Japan

Sponsors and Collaborators

Eisai Co., Ltd.

Investigators


Study Director:	Chifumi Kitamura	Morphotek Clinical Development Section, JAC PCU

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380-8. doi: 10.1007/s10637-014-0196-0. Epub 2014 Dec 12.


Responsible Party:	Eisai Co., Ltd.
ClinicalTrials.gov Identifier:	NCT01018784 History of Changes
Other Study ID Numbers:	MORAB-009-J081-102
First Submitted:	November 23, 2009
First Posted:	November 25, 2009
Last Update Posted:	January 21, 2016
Last Verified:	January 2016

Keywords provided by Eisai Inc. ( Eisai Co., Ltd. ):


Cancer Mesothelin-positive

Additional relevant MeSH terms:


Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs

To Top